# CDK9

## Overview
Cyclin-dependent kinase 9 (CDK9) is a gene that encodes the protein cyclin-dependent kinase 9, a member of the cyclin-dependent kinase family, which plays a pivotal role in the regulation of transcription. As a kinase, CDK9 is involved in phosphorylating the C-terminal domain of RNA polymerase II, a critical step in the transition from transcription initiation to elongation. This function is primarily executed as part of the positive transcription elongation factor b (P-TEFb) complex, where CDK9 associates with cyclins such as T1, T2a, or T2b. The activity of CDK9 is tightly regulated through interactions with various proteins and complexes, including the 7SK snRNP complex and the HIV-1 Tat protein, which modulate its role in transcriptional regulation. CDK9's involvement in transcriptional control extends to its participation in co-transcriptional RNA processing and its influence on RNA polymerase II dynamics. Due to its central role in transcription, CDK9 is implicated in various cellular processes and diseases, including cancer, where its dysregulation is associated with poor prognosis in several malignancies (Egloff2021CDK9; Anshabo2021CDK9:; Wu2020Recent).

## Structure
CDK9 is a cyclin-dependent kinase with a bilobal structure typical of protein kinases, consisting of an N-terminal lobe and a C-terminal lobe. The N-terminal lobe (residues 16-108) is primarily composed of beta sheets and one alpha helix, while the C-terminal lobe (residues 109-330) contains mainly alpha helices (Anshabo2021CDK9:; Wu2020Recent). The active site, where ATP binds, is located in a cleft between these lobes, with the adenine moiety of ATP deeply inserted and stabilized by hydrophobic interactions (Kryštof2009Pharmacological).

CDK9 forms a quaternary structure by associating with cyclin T1, creating the P-TEFb complex, which is crucial for transcriptional regulation (Anshabo2021CDK9:). The interaction with cyclin T1 primarily occurs through the alpha C helix in the N-terminal lobe, which contains a conserved peptide sequence (PITALRE) essential for CDK activation (Anshabo2021CDK9:).

CDK9 undergoes post-translational modifications, including phosphorylation, which is critical for its activity. Phosphorylation of Thr186 in the activation loop is necessary for full kinase activity (Wu2020Recent). CDK9 exists in two isoforms, CDK9 42 and CDK9 55, which differ in their N-terminal extensions and subcellular localizations (Liu2004Differential; Wu2020Recent).

## Function
Cyclin-dependent kinase 9 (CDK9) is a crucial component of the positive transcription elongation factor b (P-TEFb) complex, which plays a significant role in the regulation of transcription in human cells. CDK9, in association with cyclin T1, T2a, or T2b, phosphorylates the C-terminal domain (CTD) of RNA polymerase II (RNAPII), facilitating the transition from transcription initiation to elongation. This phosphorylation is essential for the release of RNAPII from a paused state, allowing it to proceed with productive elongation and efficient synthesis of full-length mRNAs (Egloff2021CDK9).

CDK9 is involved in the phosphorylation of negative elongation factors such as NELF and DSIF, converting them into positive factors that promote transcription elongation (WANG2008Cyclin-dependent). It also plays a role in the compartmentalization of RNAPII into phase-separated biological condensates, which is important for maintaining correct transcriptional output (Egloff2021CDK9).

In addition to its role in transcription elongation, CDK9 is involved in co-transcriptional RNA processing and influences the dynamics of RNAPII near polyadenylation sites (Egloff2021CDK9). CDK9's activity is regulated by its sequestration in the 7SK snRNP complex, which acts as a reservoir for rapid activation in response to cellular stimuli (Egloff2021CDK9).

## Clinical Significance
Cyclin-dependent kinase 9 (CDK9) plays a significant role in various cancers due to its involvement in transcription regulation. Overexpression of CDK9 is linked to poor prognosis in several cancers, including acute myeloid leukemia (AML), prostate cancer, and osteosarcoma. In AML, CDK9 dysregulation is associated with increased expression of oncogenes like MYC and MCL-1, contributing to poor outcomes (Boffo2018CDK9; Mandal2021Targeting). In prostate cancer, particularly in aggressive forms such as castration-resistant prostate cancer (CRPC), CDK9 overexpression is linked to disease recurrence and metastasis (Rahman2024CDK9).

In bladder cancer, CDK9 expression varies with disease stage. High expression is observed in early-stage, low-grade tumors, potentially facilitating cancer progression by inhibiting tumor-suppressing functions. Conversely, low CDK9 expression in high-grade, muscle-invasive cancers is associated with genomic instability and poorer prognosis (Borowczak2022The).

CDK9 is also implicated in transcriptional regulation in hematological malignancies and solid tumors, where its inhibition can lead to reduced tumor growth and increased apoptosis (Wu2020Recent). Despite its potential as a therapeutic target, challenges remain due to the essential roles of CDK9 in normal cellular functions and the side effects of broad-spectrum inhibitors (Wu2020Recent).

## Interactions
CDK9, a cyclin-dependent kinase, is a key component of the positive transcription elongation factor b (P-TEFb) complex, which includes cyclin T1 or T2. This complex is crucial for the phosphorylation of the C-terminal domain of RNA polymerase II, facilitating transcription elongation (Romano2008Role; Nguyen20017SK). CDK9 interacts with the 7SK small nuclear RNA (snRNA) and HEXIM1 protein, forming an inhibitory complex that sequesters P-TEFb in an inactive state. This interaction is reversible and modulates CDK9 activity, with 7SK snRNA acting as a regulatory factor (Michels2004Binding; Nguyen20017SK).

CDK9 also interacts with the HIV-1 Tat protein, which enhances its binding to TAR RNA, a critical step for HIV transcriptional regulation (Wei1998A). The interaction with Tat competes with HEXIM1, converting P-TEFb into an active form to stimulate HIV-1 transcription (Zhou2006The). Additionally, CDK9 forms complexes with bromodomain protein 4 (BRD4), which facilitates the recruitment of P-TEFb to chromatin, enhancing transcriptional elongation (Zhou2006The; Egloff2021CDK9). These interactions highlight CDK9's role in transcription regulation and its involvement in various cellular processes and diseases.


## References


[1. (WANG2008Cyclin-dependent) S WANG and P FISCHER. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends in Pharmacological Sciences, 29(6):302–313, June 2008. URL: http://dx.doi.org/10.1016/j.tips.2008.03.003, doi:10.1016/j.tips.2008.03.003. This article has 174 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.tips.2008.03.003)

[2. (Liu2004Differential) Hongbing Liu and Christine H. Herrmann. Differential localization and expression of the cdk9 42k and 55k isoforms. Journal of Cellular Physiology, 203(1):251–260, September 2004. URL: http://dx.doi.org/10.1002/jcp.20224, doi:10.1002/jcp.20224. This article has 56 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcp.20224)

[3. (Rahman2024CDK9) Razia Rahman, Muhammed H. Rahaman, Adrienne R. Hanson, Nicholas Choo, Jianling Xie, Scott L. Townley, Raj Shrestha, Ramin Hassankhani, Saiful Islam, Susanne Ramm, Kaylene J. Simpson, Gail P. Risbridger, Giles Best, Margaret M. Centenera, Steven P. Balk, Ganessan Kichenadasse, Renea A. Taylor, Lisa M. Butler, Wayne D. Tilley, Simon J. Conn, Mitchell G. Lawrence, Shudong Wang, and Luke A. Selth. Cdk9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer. British Journal of Cancer, 131(6):1092–1105, August 2024. URL: http://dx.doi.org/10.1038/s41416-024-02810-8, doi:10.1038/s41416-024-02810-8. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41416-024-02810-8)

[4. (Anshabo2021CDK9:) Abel Tesfaye Anshabo, Robert Milne, Shudong Wang, and Hugo Albrecht. Cdk9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents. Frontiers in Oncology, May 2021. URL: http://dx.doi.org/10.3389/fonc.2021.678559, doi:10.3389/fonc.2021.678559. This article has 78 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.678559)

[5. (Wei1998A) Ping Wei, Mitchell E Garber, Shi-Min Fang, Wolfgang H Fischer, and Katherine A Jones. A novel cdk9-associated c-type cyclin interacts directly with hiv-1 tat and mediates its high-affinity, loop-specific binding to tar rna. Cell, 92(4):451–462, February 1998. URL: http://dx.doi.org/10.1016/s0092-8674(00)80939-3, doi:10.1016/s0092-8674(00)80939-3. This article has 979 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0092-8674(00)80939-3)

[6. (Wu2020Recent) Tizhi Wu, Zhen Qin, Yucheng Tian, Jubo Wang, Chenxi Xu, Zhiyu Li, and Jinlei Bian. Recent developments in the biology and medicinal chemistry of cdk9 inhibitors: an update. Journal of Medicinal Chemistry, 63(22):13228–13257, August 2020. URL: http://dx.doi.org/10.1021/acs.jmedchem.0c00744, doi:10.1021/acs.jmedchem.0c00744. This article has 59 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/acs.jmedchem.0c00744)

[7. (Nguyen20017SK) Van Trung Nguyen, Tamás Kiss, Annemieke A. Michels, and Olivier Bensaude. 7sk small nuclear rna binds to and inhibits the activity of cdk9/cyclin t complexes. Nature, 414(6861):322–325, November 2001. URL: http://dx.doi.org/10.1038/35104581, doi:10.1038/35104581. This article has 562 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/35104581)

[8. (Egloff2021CDK9) Sylvain Egloff. Cdk9 keeps rna polymerase ii on track. Cellular and Molecular Life Sciences, June 2021. URL: http://dx.doi.org/10.1007/s00018-021-03878-8, doi:10.1007/s00018-021-03878-8. This article has 52 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-021-03878-8)

[9. (Michels2004Binding) Annemieke A Michels, Alessandro Fraldi, Qintong Li, Todd E Adamson, François Bonnet, Van Trung Nguyen, Stanley C Sedore, Jason P Price, David H Price, Luigi Lania, and Olivier Bensaude. Binding of the 7sk snrna turns the hexim1 protein into a p-tefb (cdk9/cyclin t) inhibitor. The EMBO Journal, 23(13):2608–2619, June 2004. URL: http://dx.doi.org/10.1038/sj.emboj.7600275, doi:10.1038/sj.emboj.7600275. This article has 245 citations.](https://doi.org/10.1038/sj.emboj.7600275)

[10. (Romano2008Role) Gaetano Romano and Antonio Giordano. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle, 7(23):3664–3668, December 2008. URL: http://dx.doi.org/10.4161/cc.7.23.7122, doi:10.4161/cc.7.23.7122. This article has 92 citations and is from a peer-reviewed journal.](https://doi.org/10.4161/cc.7.23.7122)

[11. (Mandal2021Targeting) Ranadip Mandal, Sven Becker, and Klaus Strebhardt. Targeting cdk9 for anti-cancer therapeutics. Cancers, 13(9):2181, May 2021. URL: http://dx.doi.org/10.3390/cancers13092181, doi:10.3390/cancers13092181. This article has 62 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13092181)

[12. (Borowczak2022The) Jędrzej Borowczak, Krzysztof Szczerbowski, Mateusz Maniewski, Marek Zdrenka, Piotr Słupski, Paulina Antosik, Sylwia Kołodziejska, Marta Sekielska-Domanowska, Mariusz Dubiel, Magdalena Bodnar, and Łukasz Szylberg. The prognostic role of cdk9 in bladder cancer. Cancers, 14(6):1492, March 2022. URL: http://dx.doi.org/10.3390/cancers14061492, doi:10.3390/cancers14061492. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers14061492)

[13. (Zhou2006The) Qiang Zhou and Jasper H. N. Yik. The yin and yang of p-tefb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiology and Molecular Biology Reviews, 70(3):646–659, September 2006. URL: http://dx.doi.org/10.1128/mmbr.00011-06, doi:10.1128/mmbr.00011-06. This article has 223 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mmbr.00011-06)

[14. (Boffo2018CDK9) Silvia Boffo, Angela Damato, Luigi Alfano, and Antonio Giordano. Cdk9 inhibitors in acute myeloid leukemia. Journal of Experimental &amp; Clinical Cancer Research, February 2018. URL: http://dx.doi.org/10.1186/s13046-018-0704-8, doi:10.1186/s13046-018-0704-8. This article has 110 citations.](https://doi.org/10.1186/s13046-018-0704-8)

15. (Kryštof2009Pharmacological) Ref Kryštof2009Pharmacological. This article has 32 citations and is from a domain leading peer-reviewed journal.